Taproot Edmonton’s Post

Poolbeg Pharma plc (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Thomas Warner from Proactive after announcing the #pharma & #biotech company announced some progress on lead asset, POLB 001. Skillington, fresh from the #JPMorgan conference in San Francisco, announces "very positive" in vivo data for #POLB001, showing efficacy in reducing #cancer immunity-induced #CytokineReleaseSyndrome (CRS). This development bolsters the company's hypothesis and strengthens their patent applications in this area. Skillington highlighted POLB 001's dual role as both a preventative and a treatment for #CRS, a notable advancement since no approved preventative therapies currently exist for this condition. This development could significantly benefit patients and ease healthcare system burdens. With its potential as an oral therapy, POLB 001 stands out in a market dominated by injectable treatments, offering the convenience of at-home administration. Further enhancing Poolbeg's strategic position, the addition of David Allmond as Chief Business Officer and the formation of a scientific advisory board have provided valuable insights for program positioning and market needs. Finally, Skillington discusses the immense market potential for POLB 001, estimating it at $1 billion, particularly in treating #MultipleMyeloma, high-grade #lymphoma, and acute #LymphoblasticLeukemia. Watch at #Proactive #ProactiveInvestors #AIM #OTCQB #POLB #POLBF #PoolbegPharma https://ow.ly/ZxP550Qs2nF

An interesting read to round out the week from #LifeSciencesAffectsUsAll! 🧪 From Eli Lilly and Novo Nordisk to new players on the scene, explore the latest trends and breakthroughs in obesity therapeutics, including groundbreaking trials, major investments, and key partnerships. ✨ #ObesityTherapies #HealthInnovation #ClinicalTrials #LifeSciencesNews

An interesting read to round out the week from #LifeSciencesAffectsUsAll! 🧪 From Eli Lilly and Novo Nordisk to new players on the scene, explore the latest trends and breakthroughs in obesity therapeutics, including groundbreaking trials, major investments, and key partnerships. ✨ #ObesityTherapies #HealthInnovation #ClinicalTrials #LifeSciencesNews

An interesting read to round out the week from #LifeSciencesAffectsUsAll! 🧪 From Eli Lilly and Novo Nordisk to new players on the scene, explore the latest trends and breakthroughs in obesity therapeutics, including groundbreaking trials, major investments, and key partnerships. ✨ #ObesityTherapies #HealthInnovation #ClinicalTrials #LifeSciencesNews

An interesting read to round out the week from #LifeSciencesAffectsUsAll! 🧪 From Eli Lilly and Novo Nordisk to new players on the scene, explore the latest trends and breakthroughs in obesity therapeutics, including groundbreaking trials, major investments, and key partnerships. ✨ #ObesityTherapies #HealthInnovation #ClinicalTrials #LifeSciencesNews

Exciting insights on China's NRDL 2023! Our article covers the latest developments, from oncology breakthroughs to rare disease triumphs. A must-read for anyone in healthcare. Check it out here: https://ow.ly/NUhi30szl8B #Healthcare #Pharma #Biotech #MarketStrategy #SimonKucher

Exciting insights on China's NRDL 2023! Our article covers the latest developments, from oncology breakthroughs to rare disease triumphs. A must-read for anyone in healthcare. Check it out here: https://ow.ly/2wbS30syXGA #Healthcare #Pharma #Biotech #MarketStrategy #SimonKucher

Are you attending? Please look for our poster: "Critical Path Institute Expands Data Analytics to Mitochondrial and Inherited Metabolic Diseases" Wellcome Connecting Science Learning and Training Amanda Klein mitoworld.org Critical Path Institute (C-Path) #leighsyndrome #mitochondrialdisease

Join Paul Mieyal, Ph.D., CFA at BIO International Convention 2024 in San Diego on June 3-5.   Dr. Mieyal will be a panelist for the New #PainTherapeutics: Strategies for Innovation, Investment, and Collaboration session. This session addresses the #opioidcrisis head-on by exploring how the NIH, small #biotech, #biopharma, and #VCs can rejuvenate CNS & pain innovation. The session will focus on pioneering strategies, boosting investment, and fostering public-private partnerships to fuel next-gen pain therapeutics and address this critical health need. 

The Human Organs, Physiology, and Engineering (HOPE) program (2021 – 2024) was a $50M initiative bringing together experts in life sciences and engineering to advance human tissues, organoids, and scalable organ platforms. The HOPE program built a community of researchers focused on replicating complex human organs and immune system interactions with enormous implications for advancing cancer, autoimmune, and infectious disease interventions and, eventually, to bioengineered, scalably-produced, immune-tolerant organs for transplantation. This is where those researchers continue to interact about their work. Follow this page to see their progress, publications, event announcements, and transitions. Learn more about how HOPE could transform healthcare by reducing drug development costs and addressing the organ transplant waitlist crisis. https://lnkd.in/gnUjN6Ai #OrganTransplant #Bioengineering #HOPEProgram #LifeSciences #HealthcareInnovation #WellcomeLeap